| Document |
Document Title |
|
WO/2007/051408A1 |
Compounds represented by the general formula (I), pharmaceutically acceptable salts, preparation methods, combinations and kits thereof are disclosed. The compounds can control the activity of Leucyl aminopeptidase to prevent the growth ...
|
|
WO/2007/033266A2 |
Pharmaceutical compositions comprising 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-
dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of m...
|
|
WO/2007/031213A1 |
Novel dioxazine- and oxadiazine-substituted arylamides of the formula (I) in which A1, A2, R1, R2, R3, R4 and R5 are as defined in the description, a plurality of processes for preparing these compounds and their use for controlling pest...
|
|
WO/2007/025999A1 |
There is provided, inter alia, a method for the treatment or prevention of an inflammatory skin condition which is characterised by colonisation with Staphylococcus aureus, comprising the topical administration of an aureolysin inhibitor.
|
|
WO/2007/024869A2 |
A catalyst is preparable from a first component represented by R'C(CF2R)O-Q+ and a second component (NCCFR'')bZ. The catalyst may be combined with a fluoropolymer having nitrogen-containing cure-sites to form a curable composition that i...
|
|
WO/2007/008994A2 |
The present invention relates to compounds of the formula (I), which are modulators of metalloproteinase activity. and pharmaceutically acceptable salts thereof, wherein W is -C(O)-, -OC(O)-, -NHC(O)-, -C(O)O-, Or -C(O)NH-; R1 is phenyl,...
|
|
WO/2007/000383A1 |
Biphenyl and phenyl-naphthyl compounds bearing a hydroxamic group, which are endowed with antitumour, and anti-angiogenic activity These compounds are therefore particularly useful for the treatment of drug-resistant tumours.
|
|
WO/2007/001211A2 |
The invention relates to dicarbonic acid derivatives, in particular to monooximides and dicarbonic acid dioxydiamides which are physiologically active substances and can be used in the form of low-toxic and non-toxic agents for enhancing...
|
|
WO/2006/134469A1 |
This invention relates to methods of preparing MEK inhibitor N-[(R)-2,3-dihydroxy-propoxy]-3,4- difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide that useful for treating diseases mediated by MEK activity in mammals. The present inventi...
|
|
WO/2006/117549A1 |
Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers, wherein R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intr...
|
|
WO/2006/117548A1 |
Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers: formula (I) wherein Y1 is a bond, -(C=O)-, -S(O2)-, -C(=O)O-, -OC(=O)-, -(C=O)NR3, -NR3(C=O)-, -S(O2)NR3-,...
|
|
WO/2006/097279A1 |
The present invention relates to new amidrazone compounds which are useful for combating animal pests, in particular insects, arachnids and nematodes. The invention also relates to a method for combating insects, nematodes and arachnids....
|
|
WO/2006/090153A1 |
A process for preparing a protected amidine group of formula (I): wherein R6 represents, for example, C1-10 alkyl (optionally substituted), aryl, C1-3 alkylaryl or C1-3 alkyloxyaryl; which comprises reacting a nitrile containing compound...
|
|
WO/2006/084031A1 |
The present invention provides a class of chemical compounds useful in the treatment of sickle cell disease, diseases characterized by unwanted or abnormal cell proliferation and for the treatment of ocular disorders such as glaucoma. Th...
|
|
WO/2006/070878A1 |
It is intended to provide a compound which has an anticoagulant effect based on the inhibition of the activated blood coagulation factor VII and, therefore, is useful as a blood coagulation inhibitor or a preventive/remedy for diseases c...
|
|
WO/2006/040625A1 |
The present invention relates to novel compounds useful as dipeptidyl peptidase IV (DPP-IV) inhibitors of the formula: (I) wherein Y is -S(O)m, -CH2-, CHF, or -CF2; m is 0, 1, or 2; X is a bond, C1-C5 alkyl (e.g., -CH2-), or -C(=0)-; the...
|
|
WO/2006/038606A1 |
Disclosed are a compound represented by the formula (I) below, a pharmaceutically acceptable salt thereof, a solvate of those, and a pharmaceutical composition containing such a compound. (In the formula, X1 represents N or CR2; X2 repre...
|
|
WO/2006/037761A1 |
New inhibitors of histone deacetylases having antitumor activity, and the process of preparation thereof are herein described. These compounds belong to the structural formula (I) where R1 is a linear or branched chain containing at leas...
|
|
WO/2006/027135A1 |
The invention is concerned with novel 4-aminomethyl benzamidine derivatives of formula (I) wherein Ar and X are as defined in the description and in the claims, as well as prodrugs and pharmaceutically acceptable salts thereof. These com...
|
|
WO/2006/017214A2 |
The present invention relates to hydroxamic acid derivatives that are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are useful for treating cellular proliferative diseases, including cancer. Further, th...
|
|
WO/2006/011466A1 |
Disclosed are a compound and pharmaceutically acceptable salts thereof represented by the general formula (1) below. (In the formula (1), R1, R2, R3, R4 and X are the same as R1, R2, R3, R4 and X defined in the description.)
|
|
WO2001085170A9 |
PDF inhibitors and novel methods for their use are provided.
|
|
WO/2006/003068A2 |
Compounds of the formula (I) are described in which Z, Q, X, L, m and n assume the meanings stated in the description. The compounds (I) inhibit the production of TNF &agr and may thus be useful in the treatment of inflammation and patho...
|
|
WO/2006/002506A1 |
Therapeutic polymers containing hydroxamate group that binds and thus inhibits zinc containing enzymes such as matrix metalloproteinases. The implantation fo such material inhibits remodeling in its vicinity.
|
|
WO/2005/107762A2 |
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.
|
|
WO/2005/097747A1 |
The present invention is directed to prodrugs of hydroxamic acid based histone deacetylase (HDAC) inhibitors, e.g., suberoylanilide hydroxamic acid (SAHA). The prodrugs are acylated derivatives having increased aqueous solubility and cel...
|
|
WO/2005/087710A1 |
A compound represented by the formula (1) (wherein the symbols are the same as defined in the description), a salt thereof, and a prodrug thereof. They unexpectedly have excellent GPR40 receptor agonistic activity and are excellent in pr...
|
|
WO/2005/073180A1 |
[PROBLEMS] To provide a novel compound which inhibits the generation of AGE and an AGE generation inhibitor containing the compound. [MEANS FOR SOLVING PROBLEMS] The compound is one represented by the following formula or a pharmaceutica...
|
|
WO/2005/063689A1 |
A compound which has high angiogenesis inhibitory activity and is useful in therapeutic and preventive drugs which are effective in diseases accompanied by diseased angiogenesis, e.g., cancers and the metastasis of cancers; a process for...
|
|
WO/2005/061501A2 |
Processes for preparing 10-amino-3-hydroxy-4-oxo-4,6,7,8,9,10-hexahydropyrimido[1,2-
a]azepine-2-carboxylates and related compounds are disclosed. The preparation of carboxamide derivatives from these carboxylates is also disclosed. The ...
|
|
WO/2005/058803A1 |
The present invention relates to compounds and methods for inhibiting histone deacetylase enzymatic activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and...
|
|
WO/2005/055928A2 |
Zn2+ -chelating motif-tethered fatty acids as histone deacetylase (HDAC) inhibitors. Compounds performed well in in vitro and in vivo tests.
|
|
WO/2005/053628A1 |
Use of osteopontin for reducing plaque bacterial growth on tooth enamel and dental formulations containing osteopontin.
|
|
WO/2005/054179A2 |
The invention relates to compounds of general formula I wherein D, E, F, G, W, Y R1, A, R9, X, B, R8 are as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use-alone or in combination with one or...
|
|
WO/2005/053610A2 |
The present invention relates to a novel class of hydroxamic acid derivatives having a diamine or iminodiacetic acid backbone. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit hist...
|
|
WO/2005/051947A1 |
The invention relates to novel macrocycles of general formula (I) and to the use thereof for treating cancerous diseases.
|
|
WO/2005/051901A1 |
The present invention provides compounds having the strucutural formula (I) and methods for the treatment of cancer using compounds of formula (I).
|
|
WO/2005/040098A1 |
This invention provides a novel polymorphic form of N-[(R)-2,3-Dihydroxy-propoxy]3,4-difluoro-2-(2-fluoro-4-io
do-phenylamino)-benzamide, as well a pharmaceutical compositions and therapeutic methods utilizing the polymorphic form.
|
|
WO/2005/039498A2 |
The present invention relates to methods of treating cancers, e.g., leukemia. More specifically, the present invention relates to methods of treating acute and chronic leukemias including Acute Lymphocytic Leukemia (ALL), Acute Myeloid L...
|
|
WO/2005/037779A2 |
The invention relates to medicinally used substances which specifically inhibit peptidases splitting Gly-Pro-p-nitroanilide. The invention further relates to the use of at least one such substance or at least one pharmaceutical or cosmet...
|
|
WO/2005/037257A2 |
The invention relates to medicinally used substances which specifically inhibit peptidases splitting ala-p-nitroanilide. The invention further relates to the use of at least one such substance or at least one pharmaceutical or cosmetic c...
|
|
WO/2005/033065A1 |
Novel amidine and diamidine compounds are useful in the treatment of microbial infections, including mycobacterial, fungal and protozoal infections. Pharmaceutical formulations comprising these compounds can be used in methods of treatin...
|
|
WO/2005/028426A1 |
A compound of the present invention and pharmaceutically acceptable salts thereof are represented by the following general formula (1). (1) (In the formula (1), the definitions of R1, R2, R3, R4, R5, R6, Q, R8 and R9 are the same as thos...
|
|
WO/2005/026108A1 |
A method for producing N,N'-dialkoxy-N,N'-dialkyl oxamide represented by the general formula (3): wherein R2 and R3 are as defined below, is characterized in that an oxalate diester represented by the general formula (1): wherein R1 and ...
|
|
WO/2005/025619A1 |
The invention relates to a method of preventing or treating proliferative diseases such as cancer in a mammal, particularly a human, with a combination of pharmaceutical agents which comprises: (a) an HDAI; and (b) a death receptor ligan...
|
|
WO/2005/019174A1 |
The present invention is directed to certain hydroxamate derivatives that are inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositio...
|
|
WO/2005/019194A1 |
Compounds of formula (I) are inhibitors of matrix metalloproteinases, and are of use in the treatment of, for example fibrotic disease, multiple sclerosis, emphysemia, bronchitis and asthma: formula (I) wherein Ar represents an optionall...
|
|
WO/2005/019162A1 |
The present invention provides hydroxamic acid derivatives represented by the following formula (I), having anti-aging efficacy and a method for preparation thereof: wherein, R1 is or, herein, R5 and R6 each independently represents a hy...
|
|
WO/2005/009940A1 |
The invention provides novel compounds according to formula I relates to compounds with the general formula I said compounds being useful, e.g. in the treatment of inflammatory, ophthalmic diseases or cancer.
|
|
WO/2005/007091A2 |
One aspect of the invention relates to HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided. The invention also provides methods for treating cancer and methods for treating neu...
|
